Daltro, Ramona Tavares, Santos, Emily Ferreira, Silva, Ângelo Antônio Oliveira, Maron Freitas, Natália Erdens, Leony, Leonardo Maia, Vasconcelos, Larissa Carvalho Medrado, Luquetti, Alejandro Ostermayer, Celedon, Paola Alejandra Fiorani, Zanchin, Nilson Ivo Tonin, Regis-Silva, Carlos Gustavo, and Santos, Fred Luciano Neves more...
Background: Chagas disease (CD) is caused by Trypanosoma cruzi. The chronic phase of CD is characterized by the presence of IgG anti-T. cruzi antibodies; and diagnosis is performed by serological methods. Because there is no realible test that can be used as a reference test, WHO recommends the parallel use of two different tests for CD serodiagnosis. If results are inconclusive, samples should be subjected to a confirmatory test, e.g., Western blot (WB) or PCR. PCR offers low sensitivity in the chronic phase, whereas few confirmatory tests based on the WB method are commercially available worldwide. Therefore, new diagnostic tools should be evaluated to fill the gap in confirmatory tests CD. In recent years, four chimeric recombinant antigens (IBMP-8.1, IBMP-8.2, IBMP-8.3 and IBMP-8.4) have been evaluated in phase I, II and III studies using ELISA, liquid microarray and immunochromatography with 95–100% accuracy. Given the high diagnostic performance of these antigens, the present study investigated the ability of these molecules to diagnose chronic CD using a WB testing platform. Methodology/Principal findings: In this study, we analyzed the diagnostic potential of four chimeric antigens using 40 T. cruzi-positive, 24-negative, and three additional samples positive for visceral leishmaniasis (i.e., potentially cross-reactive) using WB as the diagnostic platform. Checkerboard titration with different dilutions of antigens, conjugated antigens, and serum samples was performed to standardize all assays. All IBMP antigens achieved 100% sensitivity, specificity, and accuracy, with the exception of IBMP-8.3, which had 100% specificity despite lack of significance, but lower sensitivity (95%) and accuracy (96.9%). No cross-reactivity was observed in samples positive for leishmaniasis. Conclusions/Significance: The present phase I (proof-of-concept) study demonstrated the high diagnostic potential of these four IBMP antigens to discriminate between T. cruzi-positive and -negative samples, making them candidates for phase II and confirmatory testing with WB. Author summary: Chagas disease is a neglected infection that occurs mainly in Latin American countries. Infection occurs in several ways, the most common being vector infection by kissing bugs (family Triatominae). The disease progresses in two phases: acute and chronic. Since there is no reliable test that could serve as a gold standard, WHO recommends the parallel use of two tests. Conflicting results lead to an inconclusive diagnosis. In these cases, a confirmatory test is required, such as a Western blot (WB). However, few confirmatory tests based on the WB method are commercially available worldwide. Therefore, the aim of this study was to evaluate the use of four chimeric T. cruzi proteins developed by our group (IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4) to distinguish T. cruzi positive and negative samples. Forty T. cruzi-positive samples, 24-negative, and three additional positive samples for visceral leishmaniasis were evaluated. All IBMP antigens achieved 100% sensitivity, specificity, and accuracy, with the exception of IBMP-8.3, which had 100% specificity despite lack of significance, but lower sensitivity (95%) and accuracy (96.9%). No cross-reactivity was observed in samples positive for leishmaniasis. The present phase I (proof-of-concept) study demonstrated the high diagnostic potential of these four IBMP antigens to discriminate between T. cruzi-positive and -negative samples, making them candidates for phase II and confirmatory testing with WB. [ABSTRACT FROM AUTHOR] more...